Erectile dysfunction

Article Abstract:

Erectile dysfunction, commonly known as impotence, has many causes. It can be caused by psychological factors, neurologic diseases, hormonal imbalances, diseases that affect blood vessels, drugs, chronic diseases, and aging. Drug treatments include male sex hormones called androgens, sildenafil (Viagra), yohimbine, phentolamine, apomorphine, trazodone, papaverine, phentolamine, alprostadil, and vasoactive intestinal polypeptide. Many of these drugs are used in combination therapy.

---

Treatment of men with erectile dysfunction with transurethral alprostadil

Article Abstract:

Injecting alprostadil directly into the urethra before intercourse appears to be successful in treating male impotence. Alprostadil is a synthetic form of prostaglandin E1. Researchers tested the treatment on 1,511 men and then taught the men how to administer the drug at home. The device consists of an applicator with a small thin stem that injects the drug into the urethra when a button is depressed. Approximately 65% of the men sustained erections sufficient for intercourse after the treatment, compared to 19% who injected a placebo. Ten percent of the men experienced mild penile pain after the injection.

Synthetic prostaglandins E

---

Oral sildenafil in the treatment of erectile dysfunction

Article Abstract:

The drug sildenafil (Viagra) may be effective in treating erectile dysfunction in men. The drug inhibits the breakdown of cyclic GMP, a naturally occurring chemical in the body that promotes penile erection. Researchers randomly assigned 225 men to take sildenafil or placebo for 32 weeks. They were started on 50 milligrams of the drug and the dose could be increased or decreased. Sixty-nine percent of the attempts at intercourse were successful in men taking the drug, compared to 22% of attempts in men taking placebo. Side effects were minimal and occurred in less than 20% of the men.

Product/Service Evaluation, Viagra (Medication), Sildenafil

Similar abstracts:

• Abstracts: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. Growth hormone for the elderly?
• Abstracts: Two hundred ninety consecutive cases of multifetal pregnancy reduction: Comparison of the transabdominal versus the transvaginal approach
• Abstracts: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. Thrombotic thrombocytopenic purpura associated with clopidogrel
• Abstracts: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.